Bollard Group’s CytomX Therapeutics CTMX Stock Holding History

Bollard Group’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-712	Closed	-$1K	–	278
2024 Q4	$1K	Hold	712	–	–	﹤0.01%	272
2024 Q3	$1K	Hold	712	–	–	﹤0.01%	290
2024 Q2	$1K	Hold	712	–	–	﹤0.01%	288
2024 Q1	$2K	Hold	712	–	–	﹤0.01%	283
2023 Q4	$1K	Hold	712	–	–	﹤0.01%	293
2023 Q3	$1K	Hold	712	–	–	﹤0.01%	339
2023 Q2	$1K	Hold	712	–	–	﹤0.01%	583
2023 Q1	$1K	Hold	712	–	–	﹤0.01%	276
2022 Q4	$1K	Hold	712	–	–	﹤0.01%	270
2022 Q3	$1K	Hold	712	–	–	﹤0.01%	275
2022 Q2	$1K	Hold	712	–	–	﹤0.01%	282
2022 Q1	$2K	Hold	712	–	–	﹤0.01%	422
2021 Q4	$3K	Hold	712	–	–	﹤0.01%	424
2021 Q3	$4K	Hold	712	–	–	﹤0.01%	416
2021 Q2	$5K	Hold	712	–	–	﹤0.01%	412
2021 Q1	$6K	Hold	712	–	–	﹤0.01%	418
2020 Q4	$5K	Hold	712	–	–	﹤0.01%	415
2020 Q3	$5K	Sell	712 -2,246	-76%	-$16.7K	﹤0.01%	418
2020 Q2	$25K	Buy	+2,958	New	+$27.5K	﹤0.01%	401

Other funds holding CTMX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bollard Group's CTMX Position: Q1 2025 in Review

Bollard Group sold out of CytomX Therapeutics (CTMX) in Q1 2025, closing a stake of 712 shares — an estimated $1K sold.

Bollard Group first reported a position in CTMX in Q2 2020 and held it in 19 quarters. The position peaked at $25K in Q2 2020. 66 funds tracked by Wall St. Rank hold CTMX as of Q1 2025.

Bollard Group reported no remaining CytomX Therapeutics position as of Q1 2025 after selling out during the quarter.
Bollard Group sold 712 CytomX Therapeutics shares in Q1 2025, an estimated $1K.
Bollard Group first reported a position in CytomX Therapeutics in Q2 2020 and held it in 19 quarters.
Bollard Group's CytomX Therapeutics position peaked at $25K in Q2 2020.
66 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2025.

Based on Bollard Group's 13F filing for Q1 2025, filed 15 May 2025.